



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration  
Silver Spring MD 20993

NDA 19152/S-033

**SUPPLEMENT APPROVAL**

Ranbaxy Laboratories Limited  
Attention: Usha Sankaran  
U.S. Agent for Ranbaxy Laboratories Limited  
600 College Road East  
Princeton, NJ 08540

Dear Ms. Sankaran:

Please refer to your supplemental new drug application dated November 3, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Isoptin SR (verapamil HCL) 120 mg, 180 mg, and 240 mg Sustained Release Tablets.

This supplemental new drug application provides for the following revisions to the **PRECAUTIONS** section of the package insert, as we requested in our letter dated September 10, 2009:

Under **PRECAUTIONS, Drug Interactions**:

*Clonidine*

Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. Monitor heart rate in patients receiving concomitant verapamil and clonidine.

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)(1)(i)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to, except for including the revisions indicated above and in the enclosed labeling text for the package insert. These revisions are terms of the NDA approval. For administrative purposes, please designate this submission, "**SPL for approved NDA 19152/S-033.**"

**PROMOTIONAL MATERIALS**

All promotional materials for your drug product that include representations about your drug product must be promptly revised to make it consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions to your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the following address or by facsimile at 301-847-8444:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

In addition, as required under 21 CFR 314.81(b)(3)(i), you must submit your updated final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA-2253, directly to the above address. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

### **LETTERS TO HEALTH CARE PROFESSIONALS**

If you issue a letter communicating important safety related information about this drug product (*i.e.*, a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch  
Food and Drug Administration  
5600 Fishers Lane, Room 12B05  
Rockville, MD 20857

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call:

Lori Wachter, RN, BSN  
Regulatory Project Manager  
(301) 796-3975

Sincerely,

*{See appended electronic signature page}*

Mary Ross Southworth, Pharm.D.  
Deputy Director for Safety  
Division of Cardiovascular and Renal Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

Enclosure:  
Agreed-upon labeling text

Application  
Type/Number

Submission  
Type/Number

Submitter Name

Product Name

-----  
NDA-19152

-----  
SUPPL-33

-----  
RANBAXY  
LABORATORIES  
INC

-----  
ISOPTIN SR & CALAN SR  
TABLETS

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

MARY R SOUTHWORTH  
03/31/2010